Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivir said that Meda has introduced over-the-counter (OTC) Xerese, the company's cord sore treatment in US.
Subscribe to our email newsletter
Earlier in February 2010, Meda has got exclusive license for marketing, selling and distributing Xerese in the US, Canada and Mexico for the treatment of cold sores (herpes labialis).
Medivir will receive double-digit royalties on sales in addition to funding the commercial development of Xerese and up-front and pre-launch milestones totaling $5m.
Medivir CEO Ron Long said their partner Meda has a strong commercial presence in the US and has demonstrated great success in marketing products in the US, specifically in dermatology.
" We very much look forward to the further launches of Xerese by our partner Meda in Canada and Mexico and also the launch later this year in Europe by our partner GlaxoSmithKline," Long said.